Cencora's fiscal Q3 2026 revenue rose 5.1% to $84.8B on GLP-1 and specialty drug volume. The OneOncology acquisition and a $102M opioid-liability credit lifted GAAP operating income 29.1% and EPS 11.9% to $3.94, and adjusted EPS guidance rose to $17.75–$17.95.
Revenue
$84.8B
+5.1% YoY
Net income
$764M
+11.1% YoY
Diluted EPS
$3.94
+11.9% YoY
Operating margin
1.3%
Overview
Cencora is one of the three big U.S. drug wholesalers: it buys medicines from manufacturers and delivers them to pharmacies, hospitals and doctors' offices. Revenue grew 5.1% to $84.75 billion in fiscal Q3 2026 (quarter ended June 30, 2026). Profit grew much faster than sales: GAAP operating income rose 29.1% to $1.12 billion and diluted EPS rose 11.9% to $3.94.
Two things drove the gap between sales growth and profit growth. The first is structural: in February 2026 Cencora bought OneOncology, a network of independent cancer practices, which earns far more per dollar of revenue than drug distribution. The second is a set of accounting and legal items that flatter the GAAP figure this quarter: a $102.0 million reduction of the opioid liability and a bigger LIFO inventory credit (explained below). Management's adjusted figures strip those items out. They show a smaller but still solid 17.0% rise in operating income and 12.0% adjusted EPS growth.
Key metrics: fiscal Q3 2026 (three months ended June 30)
Metric
Fiscal Q3 2026
Fiscal Q3 2025
YoY Change
Revenue
$84,754.8M
$80,663.5M
+5.1%
Gross profit
$3,607.2M
$2,907.1M
+24.1%
Gross margin
4.26%
3.60%
+0.66 pts
Operating income (GAAP)
$1,120.2M
Read 0 community reports on Cencora, or write your own.Write a report
*Adjusted EPS comes from the company's August 5, 2026 earnings release (8-K Exhibit 99.1). All other figures come from the 10-Q.
Why the margins are so thin
A drug wholesaler keeps very little of each sales dollar. Of the $84.75 billion Cencora billed this quarter, $81.15 billion was the cost of the drugs themselves. That left gross profit (revenue minus the cost of the goods sold) of 4.26 cents per dollar. After paying for warehouses, trucks, staff and other running costs, operating margin was 1.32%. Operating margin is the share of revenue left after running the business, before interest and tax. A margin that low is normal for this industry. The business model is huge volume at a tiny markup, so small shifts in product mix move profit a lot.
GLP-1s and specialty drugs: volume up, margin mix down
U.S. Healthcare Solutions revenue rose 4.9% ($3.5 billion) to $74.86 billion. The 10-Q attributes this to "overall market growth largely driven by unit volume growth." That includes more specialty drugs sold to health systems and physician practices and $2.3 billion (+25.5%) more sales of GLP-1 drugs, the diabetes and weight-loss class. GLP-1s alone account for roughly two-thirds of the segment's revenue increase in dollars.
The catch is that GLP-1s are expensive branded drugs on which the distributor earns an especially thin fee. The U.S. segment's gross margin was 3.17%, up 63 basis points (0.63 percentage points). The 10-Q says this was "primarily due to the February 2026 acquisition of OneOncology, offset in part by higher sales of GLP-1s, which have lower gross profit margins." In other words, GLP-1s add far more to revenue than to profit, and OneOncology does the opposite.
Three things held growth back: lower manufacturer prices on certain brand drugs, the 2025 loss of an oncology customer, and lower sales to Cencora's large mail-order customer as brand drugs converted to cheaper generics.
Segment performance
Segment (fiscal Q3)
Revenue
YoY
Operating income
YoY
Op. margin
U.S. Healthcare Solutions
$74,860.8M
+4.9%
$966.2M
+15.9%
1.29%
International Healthcare Solutions
$7,680.5M
+5.9%
$165.9M
+20.8%
2.16%
Other (MWI Animal Health, Profarma, etc.)
$2,253.3M
+6.9%
$108.7M
+24.8%
4.83%
Total segment operating income
n/a
n/a
$1,238.1M
+17.0%
1.46%
U.S. Healthcare Solutions: segment operating income rose $132.5 million. OneOncology and higher pharmaceutical sales drove the increase, partly offset by higher operating expenses. Company-wide distribution, selling and administrative costs jumped 27.5%, mainly because OneOncology's practice costs are now on Cencora's books. A clinic network carries far higher overheads than a warehouse network, which is the flip side of its higher gross margin.
International Healthcare Solutions: operating income rose 20.8%. In constant currency (at last year's exchange rates, per the earnings release) it rose 23.1%. Two things helped. At the European distribution business, the 10-Q cites "manufacturer price increases in a developing market country". Global specialty logistics also grew. The price-increase driver is less repeatable than volume growth.
Other: Cencora is exploring strategic alternatives for these businesses. It sold U.S. Consulting Services in April 2026, after taking a $249.5 million impairment earlier in the fiscal year. MWI Animal Health's profit got a small boost from lower depreciation after it was classified as held for sale.
OneOncology and RCA: buying higher-margin physician businesses
On February 2, 2026 Cencora took majority control of OneOncology. Total fair-value consideration was $7.39 billion, including $4.65 billion of cash, and the practice's physicians and management kept an 8% stake. OneOncology has contributed $820.0 million of revenue since the deal closed. Cencora funded it with $3.0 billion of new senior notes and $1.5 billion of term loans. The deal follows the January 2025 purchase of Retina Consultants of America (RCA), a network of retina practices, which boosted the nine-month comparison.
The deal has costs that show up below segment profit:
Interest: net interest expense rose 72.0% to $140.7 million. The main causes were the OneOncology debt and lower interest income on a smaller cash balance.
Deal and integration expenses more than doubled to $113.1 million. That includes $55.2 million of adjustments to the value of RCA and OneOncology equity units held by physicians.
A one-off accounting gain in the prior quarter: revaluing Cencora's existing OneOncology stake produced a $1.09 billion gain in fiscal Q2. That gain is why nine-month GAAP net income is up 56.5%.
One-off items: GAAP vs. adjusted
Several items make GAAP profit look better or worse than the underlying business:
Opioid liability reduction: a $102.0 million credit "related to the dismissal of opioid litigation". Net of legal fees, litigation and opioid-related items were an $88.6 million credit, compared with an $18.0 million expense a year ago. Maryland's Supreme Court vacated the earlier judgment in the City of Baltimore case, and on May 8, 2026, during this quarter, the city voluntarily dismissed its claims against Cencora with prejudice. Cencora still carries a $4.2 billion accrued opioid settlement liability, payable over 13 years.
LIFO credit: Cencora values inventory using LIFO ("last in, first out") accounting, so drug price changes flow straight into cost of goods. Falling prices on some brand drugs produced a $94.3 million credit, up from $52.1 million. It raises GAAP profit without any link to how many drugs Cencora moved.
Below operating income, other income fell to $16.9 million from $110.4 million a year earlier. The prior-year quarter included a $39.7 million share of a gain at a company Cencora partly owns (an equity-method investee) and a $27.3 million remeasurement gain.
Higher interest and lower other income offset much of the operating gain. As a result, pre-tax income rose only 11.2% while operating income rose 29.1%. The adjusted figures exclude items including LIFO, the opioid credit, deal costs and amortization of acquired intangibles. On that basis, operating income was $1,238.1 million (+17.0%, a 1.46% margin) and net income was $869.2 million, against GAAP net income of $763.5 million.
Fiscal year-to-date (nine months ended June 30, 2026)
Metric
9M FY2026
9M FY2025
YoY Change
Revenue
$249,042.8M
$237,604.3M
+4.8%
Operating income (GAAP)
$3,023.3M
$2,610.1M
+15.8%
Net income attributable to Cencora
$2,964.5M
$1,893.9M
+56.5%
Diluted EPS (GAAP)
$15.21
$9.70
+56.8%
Adjusted diluted EPS (non-GAAP)*
$13.31
$12.15
+9.5%
Net cash from operating activities
$1,687.5M
$741.7M
+127.5%
*Adjusted EPS comes from the earnings release. Most of the gap between GAAP EPS growth (+56.8%) and adjusted EPS growth (+9.5%) comes from two items: the $1.09 billion OneOncology remeasurement gain and a $381.9 million LIFO credit. Neither will repeat in the same form.
Cencora bought back $1.0 billion of stock in the nine months. Of that, $882.2 million completed its March 2024 program and $117.8 million came under a new $2.0 billion program authorized in May 2026. The earnings release says the $1 billion was repurchased in fiscal Q3. The company had previously expected to spread that amount through calendar 2026. Diluted shares were 193.9 million, down 0.7% year over year.
Takeaway: More and more of Cencora's revenue growth comes from GLP-1 volume that earns very little, and more of its profit growth is bought. OneOncology lifted U.S. gross margin by 63 basis points, but the debt that paid for it pushed net interest expense up 72%. Underlying earnings grew about 12%, per adjusted EPS. The 29% jump in GAAP operating income was inflated by the opioid credit and a larger LIFO benefit.
Guidance and outlook
The earnings release says management raised fiscal 2026 adjusted diluted EPS guidance to $17.75–$17.95, from $17.70–$17.90. Fiscal 2025 adjusted EPS was $16.00, so the new range means 11–12% growth. The rest of the guidance:
revenue growth of 4%–6%
adjusted operating income growth of 13%–14%
net interest expense of about $490 million, up from $292 million in fiscal 2025
adjusted free cash flow of about $3.0 billion
Cencora does not give GAAP guidance.
Our read: the raise is modest, $0.05 at both ends of the range. Part of it reflects share repurchases done earlier than planned, not a better operating outlook. Cencora produced $1.14 billion of adjusted free cash flow in the first nine months (per the release), so it needs roughly $1.9 billion in fiscal Q4 to reach about $3.0 billion. In the fiscal Q4 report, watch three things:
whether OneOncology keeps U.S. margins expanding as GLP-1s grow as a share of sales
how fast the new debt gets paid down
what happens with the "Other" businesses under strategic review, including MWI Animal Health